Physician profile
Barbara Rys
NPI 1639377997
$6,673.83
in general payments reported to CMS, 2019-2025
32 companies · $911 in 2025
The $911 reported for 2025 was more than what 93% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,844 · 2022: $1,198 · 2023: $1,295 · 2024: $1,425 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,110.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $982.11 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $567.60 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $559.44 | 2021-2025 | |
| Pfizer INC. | $508.85 | 2021-2025 | |
| Novo Nordisk INC | $501.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.24 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $277.12 | 2021-2024 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $264.73 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $238.83 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $191.88 | 2021-2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $182.15 | 2021-2023 | |
| Abbott Laboratories | $111.12 | 2024-2025 | Freestyle Libre |
| Bausch Health US, LLC | $85.52 | 2021 | |
| Currax Pharmaceuticals LLC | $77.90 | 2021-2023 | Onzetra Xsail, Contrave |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $76.06 | 2023-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $72.98 | 2021-2023 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.66 | 2021 | |
| Phathom Pharmaceuticals, INC. | $45.24 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $45.08 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $43.13 | 2022 | |
| Eisai INC. | $32.85 | 2021 | |
| Medtronic, INC. | $28.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.81 | 2022 | |
| Dexcom, INC. | $25.06 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $24.99 | 2024 | Auvelity |
| Aimmune Therapeutics, INC. | $24.83 | 2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $24.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2022 | |
| Exact Sciences Corporation | $16.92 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.04 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Rys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.